Virax Biolabs Collaborates with Emory University to Advance Long COVID Diagnostic Studies
ByAinvest
Tuesday, Aug 26, 2025 7:18 am ET1min read
VRAX--
Virax Biolabs has signed a research pact with Emory University's ADJUST Center to advance clinical studies of its proprietary T cell testing technology, ViraxImmune, for diagnosing long COVID. The studies will focus on immune profiling in individuals with post-viral syndromes, and the collaboration aligns with Virax's preparations for a pre-submission meeting with the FDA. The partnership aims to validate ViraxImmune in real-world patient populations and create long-term value for shareholders.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet